Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- (-) Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- (-) Health Spending
- Health Spend Management
- High-Deductible Health Plans
- (-) Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- (-) Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Display Only
Showing 203 Results
Survey Data Shows Physicians See Pharmaceuticals as Leading Contributor to Improved Health Outcomes
Research by RTI Health Solutions and the National Pharmaceutical Council shows the value of biopharmaceutical and pharmaceutical innovations to improving patient health.
Context Matters on Health Statistics
A single number doesn’t always tell the full story, and that’s the case when it comes to a recent report from AHIP asking how our health care premium dollars are being spent.
Financial Impact of HSA-HDHP Reform to Improve Access to Chronic Disease Management Medications
According to an issue brief from VBID Health, providing pre-deductible coverage for medicines used to treat common chronic conditions could lower out-of-pocket costs and increase medication adherence…
High Spending Growth Rates For Key Diseases Were Driven By Technology And Demographic Factors
Research published in the June 2018 edition of Health Affairs shows that increases in health care spending on key diseases can be attributed to several factors: the use of new and often…
NPC at ISPOR 2018: Gathering and Curating Real-World Data
The use and importance of real-world evidence (RWE) in clinical decision-making has been frequently cited by Food and Drug Administration (FDA) Commissioner Dr. Scott Gottlieb, so it’s not surprising…
One Size Doesn’t Fit All: The Limitations Of Assuming Data Consistency In Health Spending
The Health Affairs Blog today published a piece from RTI International, RTI Health Solutions and National Pharmaceutical Council researchers detailing the assumptions made – and the…
NPC in Chain Drug Review: The Impact of PBM Rebates at the Pharmacy Counter
There is a mismatch between the savings pharmacy benefit managers (PBMs) boast about and the pinch patients are feeling in their pockets, as well as the disconnect between the role employers…
Managing PBMs: An Employer’s Perspective
During a webinar hosted by the Integrated Benefits Institute on March 5, Chuck Reynolds, consultant for Benfield, a Division of Gallagher Benefit Services, and Kristen Putnam, Director, Global…
Paying for Patient Care: Understanding the Costs and Benefits Now and Later
A new infographic based on a National Pharmaceutical Council peer-reviewed study explains how gaps between upfront costs and long-term savings of innovative treatments can emerge, why we need to…
NPC in Morning Consult: “Why Is Drug Spending So High?” Is the Wrong Question
In a column published in Morning Consult, NPC Chief Science Officer and Executive Vice President Robert W. Dubois, MD, PhD, explains that asking why drug spending is so high assumes that…